Vitamin D3 for Life

Live Enlightened

Article

Distinguishing Vitamin D Insufficiency from Deficiency and Sufficiency: Full Study

Previous related pageContextual Factors That Distort Vitamin D Blood Test Interpretation: Study SummaryNext related pageDistinguishing Vitamin D Insufficiency from Deficiency and Sufficiency: Study Summary
Study at a glance

What do vitamin D deficiency, insufficiency and sufficiency mean?

This review compares the labels deficiency, insufficiency and sufficiency used for vitamin D blood results. These roughly describe a low supply of vitamin D, a middle range and enough vitamin D, but organisations define their boundaries differently. The usual measurement is 25-hydroxyvitamin D. A label based on this measurement does not describe every effect of vitamin D in the body.

Why do guidelines use different vitamin D cut-offs?

The 2011 US Institute of Medicine guidance used 50 nmol/L to cover the needs of nearly all healthy people. UK guidance used 25 nmol/L to identify increased risk to bone and muscle health. The older Endocrine Society guidance used a different system of three categories. These approaches addressed different questions, so their cut-offs cannot be used interchangeably as personal targets.

What changed in the Endocrine Society’s 2024 vitamin D guideline?

The Endocrine Society’s 2024 guideline found that there was not enough evidence from trials to identify blood-level cut-offs that predict specific supplement benefits in generally healthy populations. It stopped endorsing its earlier target for everyone and insufficiency category for those populations. This does not prove that useful cut-offs are impossible in every medical situation.

Can one vitamin D category explain a person’s whole situation?

Very low levels that persist remain a concern for bone health. The evidence is less clear about one universal middle range that identifies disease. Laboratory differences and normal changes within a person can alter the label near a cut-off. Interpretation therefore depends on the guideline, the reason for testing and the person’s circumstances.

Read the full article below ↓

Distinguishing vitamin D insufficiency from deficiency and sufficiency is difficult because the three terms do not arise from one universally accepted biological switch. They are classification tools applied to a continuous biomarker, and different organisations choose boundaries for different purposes. The same 25-hydroxyvitamin D [25(OH)D] concentration can therefore be labelled differently depending on whether the question concerns population nutrient requirements, clinical risk, skeletal disease, or expected benefit from supplementation. The background concept is introduced in Vitamin D Insufficiency Explained. For a shorter version, see Distinguishing Vitamin D Insufficiency from Deficiency and Sufficiency: Study Summary.

Three labels, several different questions

Vitamin D Deficiency Definitions describes why “deficiency” itself is not a single self-defining number. A threshold may be chosen to identify increased risk of rickets or osteomalacia, biochemical disturbance, secondary hyperparathyroidism, inadequate population intake, or another outcome. Those are related questions, but they are not interchangeable.

“Sufficiency” creates the mirror-image problem. Vitamin D Sufficiency Explained can mean adequate for the nutrient requirements of nearly all people, above a lower-risk range for a chosen skeletal outcome, or simply not classified as deficient. It does not automatically mean “optimal for every possible outcome.” Insufficiency is then left between two boundaries whose definitions may themselves differ.

This is why the same laboratory result can be described as inadequate under one framework and adequate under another without either framework necessarily containing a numerical error. They may be answering different questions.

The IOM/NASEM framework: population adequacy, not an optimisation target

The 2011 Institute of Medicine review based vitamin D requirements primarily on skeletal health. It concluded that a serum 25(OH)D concentration of at least 20 ng/mL (50 nmol/L) would meet the requirements of at least 97.5% of the North American population under the assumptions used to derive the dietary reference intakes. It also cautioned that higher concentrations were not consistently associated with greater benefit.

That framework is frequently misunderstood. A population requirement is not the same as a personal target and is not a diagnosis. Population Reference Ranges Explained explains why population-derived boundaries describe probabilities and coverage rather than an individual physiological guarantee.

The 2011 Endocrine Society framework used a different clinical classification

The Endocrine Society’s 2011 guideline defined deficiency as 25(OH)D below 20 ng/mL and insufficiency as 21 to 29 ng/mL, with 30 ng/mL and above treated as sufficient within that guideline. The rationale drew partly on PTH relationships and calcium-absorption evidence. This produced the widely used 20/30 ng/mL three-part classification.

But the guideline itself acknowledged limitations in the evidence for these thresholds. Subsequent work continued to show wide variation in PTH breakpoints and inconsistent evidence for a specific calcium-absorption threshold at 30 ng/mL. The classification was therefore useful operationally but never equivalent to a discovered universal biological boundary.

The 2024 Endocrine Society changed its position

The 2024 Endocrine Society guideline replaced the 2011 guideline for its scope and evaluated whether baseline 25(OH)D thresholds identify generally healthy people who derive outcome-specific benefit from vitamin D supplementation. The panel concluded that clinical trial evidence did not establish such thresholds for the populations it examined and suggested against routine 25(OH)D testing in generally healthy adults in several age groups.

In an accompanying 2024 guideline communication, the Society explicitly stated that it no longer endorses its previous definition of vitamin D sufficiency as at least 30 ng/mL or its previous 20 to 30 ng/mL “insufficiency” category as an actionable designation for generally healthy individuals. This is a major interpretive change: it does not prove that thresholds are biologically impossible, but it acknowledges that available trial evidence does not justify treating the old band as a universal action threshold.

The shift is a practical example of Why Vitamin D Deficiency Cut-Offs Differ Between Guidelines. Guidance can change because the question, evidence base and evidentiary standard change.

The UK framework uses a lower population-protective level

The UK Scientific Advisory Committee on Nutrition reviewed musculoskeletal outcomes and concluded that risk of poor musculoskeletal health increases below 25 nmol/L. It used 25 nmol/L as a population-protective level for deriving the UK reference nutrient intake. SACN also cautioned that this value should not be mistaken for a precise clinical disease threshold.

This creates an obvious contrast with frameworks that use 50 nmol/L or 75 nmol/L as important boundaries. The difference is not resolved simply by choosing the highest number. The relevant question is what each threshold is designed to accomplish and what evidence supports that use.

Physiological evidence also resists a single three-bin model

Sai and colleagues found no universal PTH suppression point, and the literature they reviewed showed a wide range of reported thresholds. Gallagher and colleagues found only a small increase in calcium absorption across a large rise in 25(OH)D and no reduced-absorption threshold between 10 and 66 ng/mL. Shah and colleagues identified clearer biochemical abnormalities below about 30 nmol/L but did not find evidence of bone disease across the broad 30 to 75 nmol/L insufficiency range they examined.

These studies reinforce the distinction in Vitamin D Status vs Vitamin D Effect: a status category is not itself a physiological outcome. The lower the 25(OH)D concentration, the stronger the concern becomes for classical vitamin D deficiency physiology, but the transition is gradual and heterogeneous.

Assay and biological variability can move a result across a label

Classification is further complicated by measurement. Biological Noise in Vitamin D Testing describes normal biological fluctuation, while Limitations of Vitamin D Blood Tests explains analytical and physiological limitations of a single blood test. A result near a threshold can move between categories because of season, recent exposure, assay variation or ordinary within-person fluctuation without a matching step-change in physiology.

Why Vitamin D Results Differ is therefore clinically relevant to classification. If a category boundary is narrow, measurement uncertainty can be large enough to change the label even when the underlying biological state is essentially unchanged.

Deficiency, insufficiency and sufficiency should be interpreted by purpose

A more reliable approach is to ask what the classification is trying to do. If the purpose is to identify a range associated with clear skeletal risk, lower concentrations and accompanying biochemical or clinical features carry more weight. If the purpose is population nutrition policy, the threshold may be chosen to protect nearly all people. If the purpose is to predict benefit from supplementation in generally healthy adults, the 2024 Endocrine Society concluded that available trials do not establish a useful 25(OH)D action threshold.

This is exactly the distinction between Vitamin D Thresholds vs Targets. Thresholds are operational boundaries created for a purpose; targets imply a desired destination and require separate evidence. Confusing them can turn an administrative or population boundary into an unsupported individual treatment goal.

What can be said with confidence

There is broad agreement that very low 25(OH)D concentrations are more concerning than intermediate concentrations and that severe, prolonged vitamin D deficiency can disrupt mineral metabolism and bone mineralisation. There is much less agreement about where “insufficiency” begins or ends, especially in otherwise healthy people without classical deficiency features.

It is therefore reasonable to distinguish a severe deficiency end of the spectrum from an intermediate zone and from clearly adequate population status, but the labels should carry their evidentiary limits with them. A number alone cannot reveal which physiological process is impaired, whether an individual will benefit from treatment beyond standard intake recommendations, or whether a small difference across a threshold is biologically meaningful.

The safest interpretation combines the numerical result with its purpose, the applicable guideline, the person’s clinical context and the limitations of measurement. What Vitamin D Levels Represent provides the broader conceptual foundation: 25(OH)D is an informative status marker, not a complete readout of vitamin D function.

Scientific sources and publication details

A Catharine Ross et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53 to 58. PMID 21118827; PMCID PMC3046611; DOI 10.1210/jc.2010-2704.

Michael F Holick et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911 to 1930. DOI 10.1210/jc.2011-0385. Historical guideline; replaced by the 2024 guideline.

Marie B Demay et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907 to 1947. PMID 38828931; DOI 10.1210/clinem/dgae290. Corrected online.

Christopher R McCartney et al. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1948 to 1954.

Scientific Advisory Committee on Nutrition. SACN vitamin D and health report. UK Scientific Advisory Committee on Nutrition. 2016; current UK population guidance remains based on this report.

A J Sai et al. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health. Journal of Clinical Endocrinology & Metabolism. 2011;96(3):E436: E446. PMID 21159838; PMCID PMC3047227; DOI 10.1210/jc.2010-1886.

J Christopher Gallagher et al. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550 to 3556. PMID 22855333; PMCID PMC3462946; DOI 10.1210/jc.2012-2020.

Sonali Shah et al. Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease. Journal of Clinical Endocrinology & Metabolism. 2017;102(7):2321 to 2328. PMID 28379394; DOI 10.1210/jc.2016-3189.

Related reading

Library

Diverse Effects of Combinations of Maternal-Neonatal VDR Polymorphisms and 25-Hydroxyvitamin D Concentrations on Neonatal Birth Anthropometry: Functional Phenocopy Variability Dependence, Highlights the Need for Targeted Maternal 25-Hydroxyvitamin D Cut-Offs during Pregnancy

The aim of this study was to evaluate the combined effect of maternal and neonatal VDR polymorphisms (ApaI, TaqI, BsmI, FokI, Tru9I) and different maternal and neonatal 25(OH)D cut-offs on neonatal birth anthropometry.

Original paper ↗Read more →

Original sources

Source

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

Published in Journal of Clinical Endocrinology & Metabolism (2011).

Publication details

A Catharine Ross et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53 to 58. PMID 21118827; PMCID PMC3046611; DOI 10.1210/jc.2010-2704.

Read more →
Source

Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

Published in Journal of Clinical Endocrinology & Metabolism (2011).

Publication details

Michael F Holick et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911 to 1930. DOI 10.1210/jc.2011-0385. Historical guideline; replaced by the 2024 guideline.

Read more →
Source

SACN vitamin D and health report

Published in UK Scientific Advisory Committee on Nutrition (2016).

Publication details

Scientific Advisory Committee on Nutrition. SACN vitamin D and health report. UK Scientific Advisory Committee on Nutrition. 2016; current UK population guidance remains based on this report.

Read more →
Source

The Effect of Vitamin D on Calcium Absorption in Older Women

Published in Journal of Clinical Endocrinology & Metabolism (2012).

Publication details

J Christopher Gallagher et al. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550 to 3556. PMID 22855333; PMCID PMC3462946; DOI 10.1210/jc.2012-2020.

Read more →